COMPANY PROFILE

AM-Pharma

Explore full profile

Biopharmaceutical company developing recombinant alkanine phosphatase therapies

Bunnik, NetherlandsFounded 2002Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About AM-Pharma

AM-Pharma is a biopharmaceutical company focused on developing innovative therapeutics for acute kidney injury (AKI) and sepsis-associated conditions. The company operates in the healthcare and biotechnology market, targeting hospitals and medical research institutions as its primary clients. AM-Pharma's core product is recombinant human Alkaline Phosphatase (recAP), which is currently undergoing Phase III clinical trials. The business model revolves around the research, development, and eventual commercialization of recAP, with funding sourced from venture capital, grants, and partnerships. Revenue generation is anticipated through the successful approval and sale of recAP, as well as potential licensing agreements and collaborations with larger pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2002
Headquarters: Bunnik, Netherlands
Employees: 31
Open positions: None listed
Dealroom signal: 80.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
FundingOther financing	Jul 2021	$0	—	Undisclosed	↗
DEBTDebt	Apr 2020	$27M	—	European Investment Bank	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

AM-Pharma website traffic

Latest recorded traffic for AM-Pharma is 1.3K monthly website visits, down 35% over the last three months. AM-Pharma's team grew 6.9% over the past year.

Latest monthly visits1.3K 3-month web change-35% 1-year team growth+6.9%

Monthly website visitsFeb 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
NENeurOpResearch company developing different drug compounds	Atlanta, United States	Operational
KPKringle PharmaKringle Pharma is a late clinical-stage biopharmaceutical company focused on research and development of regenerative medicines	Toyonaka, Japan	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
EXExonateTopical small-molecule therapeutics for retinal vascular diseases	Cambridge, United Kingdom	Operational
MAMarinomedMarinomed is a biopharmaceutical company discovering and developing innovative anti-viral and immunological treatments	Gemeinde Korneuburg, Austria	Operational